Champion for health innovation
- Cause of death: fax not delivered
- How health tech can transform the post-acute care market
- Eye-tracking technologies are life links for ALS patients
- As the world grays, it’s time to ensure seniors’ tech literacy
- HIMSS21 is a “HIT” as the community comes together
- Content, common purpose and community unite patients online
Dr DJ Hamblin-Brown
CEO at Careful Systems
DJ Hamblin-Brown is the founder and CEO of CAREFUL, a SaaS platform that’s making handover safer for patients, easier for clinicians and more efficient for hospitals across the globe.
He practiced as an Emergency Physician in the NHS for many years and is a Fellow of the Royal College of Emergency Medicine in London (FRCEM). During his career, DJ has been Vice-president of Medical Affairs at United Family Healthcare (UFH) in Beijing and Group Medical Director for Aspen Healthcare in the UK.
DJ has dedicated most of his working life to the challenges of improving healthcare, is a published author and endeavours to practice as a buddhist.
Director of Partnerships at 1907 Foundation
CEO at Protelhealth
Norman, a pharmacist, and entrepreneur has been dedicated to improving medication adherence since 1991 when he established Surgichem, to design the market-leading medication management system, NOMAD. In 2008, he established a new company, Protomed to develop a new and innovative medication management system, Biodose. This was the first system to hold liquid medicines alongside tablets and capsules in one managed dosage system. Norman was a director and board member of BUPA Healthcare Services, from 1997 until 2004, where he managed the health and care recruitment businesses. His latest innovative service, PAMAN was developed for Liverpool City council and monitors patients taking their medicines, ensuring that prescribed medicines are taken when needed Norman was a board member of the European Adherence Forum, based in Vienna from 2002 until 2008 where he was involved with several pan-European initiatives to manage patient non-adherence.You can find more Paman here.
Founder & CEO Medisieve
George span out MediSieve in May 2015 and has served as its Chief Executive Officer since inception. He has a deep passion for bringing together his engineering and entrepreneurship skills to create healthcare solutions. George holds a PhD in Biochemical Engineering from University College London (UCL). He also attained a MSc in Nanotechnology from University College London (UCL) and a BSc in Physics and Philosophy from King’s College London (KCL). George was awarded a highly competitive BBSRC Enterprise Fellowship from the Royal Society of Edinburgh in 2014 and completed the Entrepreneurship Summer School programme at London Business School. Recently George was awarded BBSRC Innovator of the Year.
MediSieve is an award-winning biotech company developing “Magnetic Haemofiltration System” (MHS), a first-of-its-kind drug/device combination platform that enables the removal of specific substances from the bloodstream. MHS can be used either as a direct treatment, to increase the safety and efficacy of other therapies, or enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. We have the ambition to become a global player, providing hospitals with a new tool to tackle some of mankind’s most serious diseases.